<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Individuals with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (n = 105; age 36-71 years) on diet therapy alone, and with quite good glycaemic control (mean HbA1c approximately 7.0%) were randomized to receive <z:chebi fb="0" ids="2376">acarbose</z:chebi> (100 mg three times daily) or placebo for 16 weeks, and changes in clinical and metabolic parameters indicative of Syndrome X were monitored </plain></SENT>
<SENT sid="1" pm="."><plain>Fasting levels of <z:chebi fb="105" ids="17234">glucose</z:chebi>, glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c), true insulin, proinsulin, fibrinogen and <z:chebi fb="23" ids="18059">lipids</z:chebi> were measured four times weekly, and <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, proinsulin and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> responses to a standardized 1.6 MJ breakfast were determined at 0, 1 and 2 h post meal </plain></SENT>
<SENT sid="2" pm="."><plain>Analysis was on an intention-to-treat basis </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting levels of <z:chebi fb="105" ids="17234">glucose</z:chebi> (P &lt; 0.0001), <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (P = 0.03) and HbA1c (P = 0.003) were reduced by <z:chebi fb="0" ids="2376">acarbose</z:chebi> over the 16 weeks of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The mean change in HbA1c from week 0 to 16 differed by 0.4% (P = 0.003) between the two groups </plain></SENT>
<SENT sid="5" pm="."><plain>Insulin (P = 0.06), proinsulin (P = 0.07) and <z:chebi fb="105" ids="17234">glucose</z:chebi> (P &lt; 0.0001) responses to the standard meal were reduced </plain></SENT>
<SENT sid="6" pm="."><plain>These data show that <z:chebi fb="0" ids="2376">acarbose</z:chebi> reduces fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels, lowers HbA1c and limits the glycaemic and insulin response to food in individuals with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> with Syndrome X </plain></SENT>
<SENT sid="7" pm="."><plain>Pharmacological agents that improve the metabolic environment and reduce <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> have the potential to limit the progression of atherogenesis associated with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>